Limbix

Limbix is a prescription digital therapeutic company founded in 2016, focused on developing evidence-based mental health treatments for adolescents aged 13 to 22, particularly thos

e experiencing symptoms of depression. The company aims to provide accessible and clinically validated mental health care by combining clinical expertise with technological innovation. In July 2023, Limbix was acquired by Big Health to enhance its offerings in adolescent mental health. The primary product offered by Limbix is SparkRx, a self-guided cognitive behavioral therapy (CBT) mobile app designed for adolescents with depression. SparkRx features a multi-week CBT program that emphasizes value-based activities, mood tracking, and mindfulness. It is intended to be prescribed by licensed healthcare professionals as an adjunct treatment for depression and is available nationwide in the U.S. Limbix operates under a B2B2C model, serving both teens and young adults as end-users and healthcare professionals who prescribe SparkRx.